Perceptive Advisors

Caris Life Sciences specializes in advanced molecular profiling technologies for cancer diagnostics and drug development. Established in 1987, it offers prognostic testing services, genomic profiling, and clinico-genomic data platforms to improve patient outcomes. The company operates globally with offices in the US and Switzerland.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Zucara Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutics to prevent hypoglycemia, or low blood sugar, in patients with diabetes. Established in 2014 and headquartered in Toronto, Canada, with an additional office in Vancouver, Zucara is pioneering a once-daily treatment that aims to regulate the hormone somatostatin in the pancreas. This treatment specifically targets somatostatin type 2 receptors, which are not effectively controlled in patients with Type 1 diabetes. Zucara's approach presents a significant advancement in diabetes care by functioning as a preventative measure against hypoglycemia, contrasting with existing therapies that only provide rescue during acute episodes. Through its pre-clinical technology, Zucara Therapeutics aims to restore natural glucose levels in the blood, ultimately enhancing the quality of life for individuals living with diabetes.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Orpyx Medical Technologies Inc. is a Calgary-based company that develops innovative mobility sensor devices aimed at supporting diabetic patients in maintaining their mobility. Founded in 2010, the company offers several key products, including the Orpyx SI sensory insoles, which are designed to manage and prevent diabetic foot ulcers and limb loss by capturing real-time data related to pressure, temperature, and movement. Additionally, Orpyx provides Kinetyx, a mobile in-shoe pressure management system that collects clinical plantar pressure data for various applications, including sports medicine and therapeutic use. Another notable product is SurroGait Rx, which assists multiple sclerosis patients in improving their mobility and balance. Orpyx Medical Technologies emphasizes the importance of prevention in healthcare and collaborates with global stakeholders to promote sustainable health solutions.

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes the inherently unstable functional conformations of GPCRs, providing a robust framework for drug discovery. This innovative approach reveals previously inaccessible structural features of these receptors, facilitating the discovery of novel agonists and enhancing therapeutic interventions. By concentrating on stabilizing GPCRs, Confo Therapeutics aims to significantly advance the development of new treatments in the medical field.

InSightec Ltd. is a pioneering company based in Tirat Carmel, Israel, specializing in non-invasive medical treatments through its Exablate platform, which employs MR guided focused ultrasound technology. Founded in 1999, InSightec develops and distributes systems that address various oncology and gynecology conditions, including the Exablate Neuro for personalized thalamotomy in movement disorders and pain management. The Exablate system has received multiple regulatory approvals, including CE marks and FDA approval, for treatments of symptomatic uterine fibroids, pain from bone metastases, and adenomyosis. The company provides comprehensive support services, including onsite clinical training and maintenance, to medical professionals using its technology in facilities across Israel and internationally. InSightec maintains a strategic partnership with Lantheus Holdings and has expanded its presence in Europe, Asia, and the Americas, earning recognition for its innovative contributions to the field of acoustic surgery.

Talkiatry is a provider of virtual, in-network psychiatry services, connecting patients with a team of over 300 licensed psychiatrists. The company focuses on delivering evaluation, diagnosis, and personalized treatment plans, including medication management, for various mental health conditions such as anxiety, depression, ADHD, and substance use disorders. By employing an interactive process with evidence-based scales, Talkiatry facilitates on-the-spot preliminary diagnoses and assessments, thereby enhancing access to quality mental health care. The company's mission is to make high-quality psychiatric services both accessible and convenient for patients seeking treatment.

Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.

CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Founded in 2022, Pheon Therapeutics specializes in developing Antibody-Drug Conjugates (ADCs) for challenging-to-treat cancers. Its primary focus is a first-in-class ADC targeting a novel marker overexpressed in various solid tumors.

CinDome Pharma specializes in developing innovative treatments for individuals affected by chronic gastrointestinal disorders, with a primary focus on chronic gastroparesis.

CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.

SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

Adaptilens develops an accommodating intraocular lens that replicates the natural human lens, enabling clear near, intermediate, and distance vision without eyeglasses or contact lenses. The lens uses the eye's ciliary muscles to change shape for natural focus across distances and returns to its baseline form for distance viewing. The company is based in Chestnut Hill, Massachusetts.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Neurosterix develops innovative medicines using allosteric modulation, a method that overcomes traditional treatment limitations. Their drug discovery platform focuses on neurological disorders, aiming to improve efficacy, safety, and tolerability for patients.

Capstan Therapeutics specializes in developing innovative therapeutics using precision cell engineering for various diseases with unmet clinical needs.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies to transform the treatment of inflammatory bowel disease (IBD).

Applied Therapeutics is a biopharmaceutical company focused on developing transformative drugs targeting fatal and debilitating diseases with high unmet medical needs. Its pipeline includes novel product candidates such as AT-007 for rare metabolic diseases like galactosemia, AT-001 for diabetic cardiomyopathy, and AT-003 for diabetic retinopathy.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery. Its lead product candidate, DEXTENZA, is an ophthalmic insert that has completed Phase III clinical trials for post-surgical ocular pain, inflammation, and allergic conjunctivitis, and is also being investigated for dry eye diseases. Additionally, Ocular Therapeutix is developing several other products, including OTX-TP, an intracanalicular travoprost insert for glaucoma, and OTX-TKI, an intravitreal implant for wet age-related macular degeneration, among others. The company has established a strategic collaboration with Regeneron Pharmaceuticals to leverage its hydrogel technology in combination with Regeneron's VEGF-targeting compounds for retinal diseases. Founded in 2006 and headquartered in Bedford, Massachusetts, Ocular Therapeutix aims to address unmet needs in ophthalmology through its advanced therapeutic solutions.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Astria Therapeutics is a biopharmaceutical company focused on developing therapies for rare and niche allergic and immunological diseases. It is advancing monoclonal antibody programs such as STAR-0215, a plasma kallikrein inhibitor being developed for hereditary angioedema, and STAR-0310, an OX40 antagonist for atopic dermatitis, both in preclinical development to address immune-mediated inflammatory conditions.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies to transform the treatment of inflammatory bowel disease (IBD).

Apyx Medical Corp is a medical device company focused on energy technology, dedicated to developing, manufacturing, and marketing a variety of surgical and cosmetic products. The company is known for its innovative Renuvion cosmetic technology, which enables plastic and cosmetic surgeons to apply controlled heat to tissues, achieving desired aesthetic results with minimal invasiveness. Apyx Medical's flagship J-Plasma system utilizes a patented helium ionization process to generate a stable, focused beam of plasma, allowing for precise cutting, coagulation, and ablation of soft tissue while minimizing unintended damage to surrounding areas. Apyx Medical’s products are utilized in a range of settings, including doctor's offices, surgery centers, and hospitals, highlighting the company's commitment to enhancing surgical outcomes through advanced medical technologies.

Founded in 1987, enVVeno Medical is a late-stage medical device company specializing in bioprosthetic solutions for treating venous diseases. Its flagship product, VenoValve, is a surgical replacement venous valve currently in pivotal trials. The company is also developing enVVe, a non-surgical, transcatheter-based replacement venous valve.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.

Anteris Technologies is a medical device company focused on developing innovative solutions for structural heart conditions. It specializes in the research, development, and commercialization of cutting-edge medical devices aimed at restoring healthy heart function.

Apogee Therapeutics is a biotechnology company focused on developing therapies for immunological and inflammatory disorders. Based in San Francisco and founded in 2022, it aims to advance novel biologics to address patients’ unmet needs. The company pursues differentiated antibody programs targeting well-established mechanisms implicated in atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunology indications, supported by antibody engineering to optimize half-life and other properties.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

InSightec Ltd. is a pioneering company based in Tirat Carmel, Israel, specializing in non-invasive medical treatments through its Exablate platform, which employs MR guided focused ultrasound technology. Founded in 1999, InSightec develops and distributes systems that address various oncology and gynecology conditions, including the Exablate Neuro for personalized thalamotomy in movement disorders and pain management. The Exablate system has received multiple regulatory approvals, including CE marks and FDA approval, for treatments of symptomatic uterine fibroids, pain from bone metastases, and adenomyosis. The company provides comprehensive support services, including onsite clinical training and maintenance, to medical professionals using its technology in facilities across Israel and internationally. InSightec maintains a strategic partnership with Lantheus Holdings and has expanded its presence in Europe, Asia, and the Americas, earning recognition for its innovative contributions to the field of acoustic surgery.

MeiraGTx Holdings is a clinical-stage gene therapy company dedicated to developing and commercializing innovative gene therapy products aimed at transforming the lives of patients with acquired and inherited disorders. The company focuses on addressing serious medical conditions, primarily targeting disorders related to the eye, salivary gland, and central nervous system. Its research and development efforts leverage a portfolio approach, which includes licensing, acquiring, and developing advanced technologies to support a diverse range of product candidates. Key pipeline products include AAV-CNGB3, AAV-CNGA3, and AAV-RPGR, among others. MeiraGTx operates in the United States, the United Kingdom, and the European Union, with plans to expand its focus to develop additional gene therapy treatments for various serious diseases in the future.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

VivoSense specializes in developing wearable sensor physiological monitoring solutions for research and clinical trials. Their platform focuses on real-world digital clinical measures to enhance patient care and improve clinical research outcomes.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Omada Health is a digital healthcare company that offers personalized programs to manage chronic conditions such as prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health. It combines professional coaching, connected devices, real-time data, and personalized feedback to deliver clinically meaningful results.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, founded in 2018. The company is dedicated to developing innovative treatments that address the underlying causes of pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Endeavor BioMedicines is focused on creating a small-molecule inhibitor that has the potential to not only halt the progression of IPF but also to reverse its effects. By concentrating on these advancements, the company aims to enable healthcare professionals to provide more precise treatments for terminal conditions, ultimately improving patient outcomes and enhancing quality of life.

Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.

Founded in 2014, Sermonix Pharmaceuticals is a biotechnology company dedicated to developing and commercializing female-specific oncology products. Its primary focus is lasofoxifene, a selective estrogen receptor modulator used for treating vulvovaginal atrophy and preventing postmenopausal osteoporosis.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of innovative treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its clinical candidates toward marketing approval, CinCor seeks to provide effective solutions for patients suffering from these conditions.

Twin Health, Inc. is a precision health company that focuses on reversing diabetes and chronic diseases through its innovative health platform. Founded in 2018 and based in Mountain View, California, with additional offices in Chennai and Bengaluru, India, the company utilizes artificial intelligence and Internet-of-Things technologies to assess and restore metabolic health. Its platform analyzes complex biosignals from wearable sensors to predict metabolic outcomes and provide tailored treatment recommendations based on individual metabolic profiles. Twin Health has developed unique technology, with several patents granted and pending, that underpins its mission to normalize blood sugar levels and reduce reliance on medications.

Science 37 specializes in decentralized clinical trials, offering a technology-driven approach that enables patients to participate from their homes. The company's platform connects researchers with patients via telemedicine investigators and mobile nurses, accelerating trial enrollment and retention while reaching a more diverse patient population.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Founded in 1987, enVVeno Medical is a late-stage medical device company specializing in bioprosthetic solutions for treating venous diseases. Its flagship product, VenoValve, is a surgical replacement venous valve currently in pivotal trials. The company is also developing enVVe, a non-surgical, transcatheter-based replacement venous valve.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

Bridge to Life is a U.S.-based company headquartered in Northbrook, Illinois, dedicated to enhancing organ transplantation through the development and licensing of innovative preservation solutions and technologies. As a leading supplier of preservation products worldwide, the company focuses on advancing organ preservation and machine perfusion techniques, which are crucial for the effective storage of intra-abdominal organs. By collaborating closely with surgeons and transplant professionals, Bridge to Life continually explores emerging scientific advancements and preservation technologies to improve the quality of service provided to organ procurement organizations and transplant centers.

Bridge to Life is a U.S.-based company headquartered in Northbrook, Illinois, dedicated to enhancing organ transplantation through the development and licensing of innovative preservation solutions and technologies. As a leading supplier of preservation products worldwide, the company focuses on advancing organ preservation and machine perfusion techniques, which are crucial for the effective storage of intra-abdominal organs. By collaborating closely with surgeons and transplant professionals, Bridge to Life continually explores emerging scientific advancements and preservation technologies to improve the quality of service provided to organ procurement organizations and transplant centers.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Forge Biologics, Inc. is a contract development and manufacturing organization (CDMO) specializing in gene therapies and genetic medicines. Founded in 2019 and based in Columbus, Ohio, the company focuses on developing and manufacturing therapeutics, particularly for viral vector gene therapies aimed at treating genetic diseases. Notably, it offers a novel approach combining adeno-associated virus (AAV) and umbilical cord transplant to address infantile Krabbe disease, a severe neurodegenerative disorder. Additionally, Forge Biologics collaborates with scientists, physicians, biotech and pharmaceutical companies, and patient groups to facilitate the progression of gene therapy programs from preclinical development through to clinical and commercial-scale manufacturing. The company is committed to enabling access to transformative medicines for patients suffering from rare genetic diseases.

Renovia Inc., founded in 2016 and based in Boston, Massachusetts, was a healthcare company focused on developing prescription digital therapeutics for pelvic floor disorders. The company's innovative device provided a clinically validated treatment for conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. This technology allowed for real-time visualization of pelvic movement during muscle training sessions, facilitating a non-surgical and drug-free approach to treatment. However, Renovia ceased operations in late 2022 following a strategic review by its investors, and in January 2023, the majority of its assets, including intellectual property, were acquired by Axena Health, Inc.

Icosavax develops virus-like particle (VLP) vaccines using its proprietary computational design platform. Its primary focus is creating vaccines for life-threatening respiratory diseases, with current candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Founded in 2017, the company aims to discover, develop, and commercialize vaccines against infectious diseases.

Pyxis Oncology, established in 2019 in Boston, Massachusetts, is a biotechnology company specializing in the development of antibody therapeutics for cancer treatment. The company focuses on promoting the body's immune response to cancer by analyzing tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and tumor cell signaling pathways within cold tumors. Pyxis aims to create novel antibody-based immunotherapies to directly kill tumor cells and address underlying pathologies that enable cancer proliferation and immune evasion, with the goal of improving patient outcomes for difficult-to-treat cancers.

Crossover Health designs and delivers workplace healthcare services for employers and employees, offering primary care and a broad range of ancillary and advanced services, including urgent and preventive care, chronic disease management, health risk assessment, health education, coaching, biometrics, physical therapy, chiropractic, acupuncture, care coordination, health analytics, and remote care. It operates as a primary care medical group that blends health management services with technology-enabled tools to create a comprehensive employee care experience. Founded in 2010 and based in California, Crossover Health serves client organizations through on-site and partner health centers across Silicon Valley and other U.S. locations, with a focus on improving access to care, enhancing member experience, and reducing healthcare costs for employers and their workforce.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

DarioHealth is a digital health company that develops and commercializes patented and proprietary technology enabling smartphone-based laboratory testing and real-time diabetes management. Its flagship Dario system combines a mobile software application with a pocket-sized blood glucose monitoring device, backed by the DarioEngage platform that provides coaching, digital communications, alerts, trend analysis, and support for chronic illness management. The company markets its solutions directly to consumers and through retail pharmacies, hospitals, and distributors across international markets, with sales occurring online as well. DarioHealth operates at the intersection of life sciences, behavioral science, and software, delivering digital therapeutics-style interventions that are personalized and data-driven across diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health through a suite of software, devices, and coaching services. Established in 2011 and headquartered in Israel, DarioHealth focuses on transforming self-management of chronic conditions by integrating software, monitoring hardware, and remote coaching.

MIVI Neuroscience, Inc. is a medical device company based in Eden Prairie, Minnesota, that specializes in developing and commercializing clinical solutions for neurointerventional procedures. Founded in 2013, the company offers a range of innovative products designed to enhance patient outcomes in treating ischemic strokes. Its portfolio includes high flow tubing, diagnostic and guide catheters, distal access catheters, and aspiration pumps, as well as embolic protection and clot retrieval devices. MIVI Neuroscience focuses on providing healthcare professionals with unique tools that aim to improve the safety and efficacy of interventional therapies, ultimately reducing complications and procedure times while expanding treatment options for patients.

Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Founded in 2018, Neuron23 is a biotechnology company based in South San Francisco, California, with an additional office in Munich, Germany. It specializes in developing and manufacturing medicines for genetic disorders using artificial intelligence technology and genetics.

Founded in 2011, Adagio Medical specializes in the research, development, and manufacturing of medical devices for treating cardiac arrhythmias. Its primary product is the iCLAS (continuous lesion ablation system), along with associated catheters, esophageal balloons, and consoles.

Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.

LianBio is a biopharmaceutical company founded in 2019, headquartered in Shanghai, China, with an additional office in Princeton, New Jersey. The company is dedicated to the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as addressing other unmet medical needs in Greater China and major Asian markets. LianBio focuses on in-licensing assets and collaborates with leading partners to enhance its pipeline, which includes clinically validated product candidates across various therapeutic areas such as cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory indications. The company aims to accelerate the availability of innovative medicines to improve patient outcomes through a science-driven approach.

AavantiBio, Inc. is a biopharmaceutical company focused on developing gene transfer and gene editing therapies aimed at treating rare genetic diseases. Incorporated in 2019 and based in Gainesville, Florida, the company primarily concentrates on Friedreich’s Ataxia, a rare inherited disorder that leads to significant cardiac and central nervous system dysfunction. AavantiBio is committed to transforming the lives of patients suffering from this condition by advancing innovative therapies that address unmet medical needs in the field of genetic disorders. The company’s efforts are directed toward both treatment development and research, with the goal of providing effective solutions for patients facing the challenges of rare diseases.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative therapies for oncology, focusing on patients with difficult-to-treat cancers where conventional treatments have proven ineffective.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Taysha Gene Therapies develops adeno-associated virus-based gene therapies to treat monogenic diseases of the central nervous system. Its pipeline includes treatments for GM2 gangliosidosis, CLN1 disease, Rett syndrome, SLC6A1 haploinsufficiency disorder, and Surfeit locus 1 deficiency. The company collaborates with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Forge Biologics, Inc. is a contract development and manufacturing organization (CDMO) specializing in gene therapies and genetic medicines. Founded in 2019 and based in Columbus, Ohio, the company focuses on developing and manufacturing therapeutics, particularly for viral vector gene therapies aimed at treating genetic diseases. Notably, it offers a novel approach combining adeno-associated virus (AAV) and umbilical cord transplant to address infantile Krabbe disease, a severe neurodegenerative disorder. Additionally, Forge Biologics collaborates with scientists, physicians, biotech and pharmaceutical companies, and patient groups to facilitate the progression of gene therapy programs from preclinical development through to clinical and commercial-scale manufacturing. The company is committed to enabling access to transformative medicines for patients suffering from rare genetic diseases.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for chronic respiratory diseases with unmet medical needs. Its lead candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterases 3 and 4 that provides bronchodilation and anti-inflammatory effects in a single molecule. Development programs include formulations of ensifentrine for chronic obstructive pulmonary disease, with options such as nebulized administration, a dry powder inhaler, and a pressurized metered-dose inhaler. Verona Pharma is also pursuing development of ensifentrine for cystic fibrosis and asthma. The company was founded in 2005 and is headquartered in London, United Kingdom.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

Pear Therapeutics, Inc. is a Boston-based commercial-stage healthcare company specializing in software-based digital therapeutics, also known as Prescription Digital Therapeutics (PDTs). Founded in 2013, the company develops clinically validated software solutions designed to treat a range of behavioral health disorders, including addiction, anxiety, depression, and chronic insomnia. Its suite of products includes mobile digital therapies that reward patients for engagement, and specific tools like reSET and reSET-O, aimed at treating substance use disorders. The company also offers Somryst, which provides neurobehavioral interventions for insomnia, and operates PearConnect, a patient services center that connects patients with advocates and resources, ensuring support throughout their treatment journey. Pear Therapeutics aims to enhance treatment outcomes by integrating digital therapies with pharmaceuticals and providing comprehensive support for patients, clinicians, and payors.

Genome Medical operates a platform that connects individuals and healthcare providers with genetic specialists. It offers virtual genetic care services, including clinical consultations for various health areas like cancer, cardiology, and reproductive health. The company uses its Genome Care Delivery technology to facilitate efficient genetic assessments and personalized treatment plans.

C4 Therapeutics is a biopharmaceutical company developing targeted protein degradation therapies using its proprietary Degronimid platform. This platform enables the selective destruction of disease-causing proteins, expanding the scope of treatable conditions and potentially reducing drug resistance. The company focuses on oncology indications and has strategic collaborations with industry leaders.

C4 Therapeutics is a biopharmaceutical company developing targeted protein degradation therapies using its proprietary Degronimid platform. This platform enables the selective destruction of disease-causing proteins, expanding the scope of treatable conditions and potentially reducing drug resistance. The company focuses on oncology indications and has strategic collaborations with industry leaders.